交联辅助感染控制:一项评估辅助交联对真菌性角膜炎结局影响的随机临床试验
该随机对照试验在印度马杜赖Aravind眼科医院纳入涂片阳性真菌性溃疡伴中度视力下降的连续患者,采用2×2析因设计比较局部那他霉素5%与两性霉素B 0.15%联合或不联合角膜交联(CXL)。结果显示辅助CXL对24小时培养阳性率无显著影响,但CXL组3周和3个月最佳眼镜矫正视力更差,结论认为辅助CXL对中度丝状真菌性溃疡无获益且可能降低视力。
要点
- 辅助CXL未显著降低24小时培养阳性率(OR 1.32,95%CI 0.57-3.06,P=0.51)。
- CXL组3周BSCVA平均差约0.22 logMAR(2.2行),3个月差约0.32 logMAR(3.2行)。
- 那他霉素与两性霉素B在24小时培养阳性率上无显著差异(系数1.10,95%CI 0.47-2.54,P=0.84)。
核心结论
- 辅助CXL对中度丝状真菌性溃疡的初始治疗似乎无获益,且可能导致视力下降。
研究设计与样本
- 结局设盲、2×2析因设计、随机对照临床试验,纳入印度马杜赖Aravind眼科医院涂片阳性真菌性溃疡伴中度视力下降的连续患者。
主要发现
- 无论使用哪种药物,随机接受CXL者24小时培养阳性的比值增加1.32倍,但未达统计学显著(95%CI 0.57-3.06;P=0.51)。
- 无论是否接受CXL,随机接受两性霉素B与那他霉素者24小时培养阳性率无差异(系数1.10;95%CI 0.47-2.54;P=0.84)。
- 无论使用哪种药物,CXL组3周BSCVA平均差约0.22 logMAR(2.2行Snellen)(95%CI -0.04至0.40;P=0.04),3个月校正基线视力后差0.32 logMAR(3.2行)(95%CI 0.03-0.54;P=0.02)。
- CXL与无CXL比较或两种局部药物比较,浸润或瘢痕大小、上皮化百分比或不良事件均无差异。
临床怎么用
- 原文结论认为辅助CXL对中度丝状真菌性溃疡的初始治疗似乎无获益,且可能导致视力下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine if there is a benefit to adjuvant corneal crosslinking (CXL) and to compare natamycin versus amphotericin B for filamentous fungal keratitis. DESIGN: Outcome-masked, 2×2 factorial design, randomized controlled clinical trial. PARTICIPANTS: Consecutive patients presenting with moderate vision loss from a smear-positive fungal ulcer at Aravind Eye Hospital, Madurai, India. METHODS: Study eyes were randomized to 1 of 4 treatment combinations using an adaptive randomization protocol. The treatment arms included (1) topical natamycin 5% alone, (2) topical natamycin 5% plus CXL, (3) topical amphotericin B 0.15% alone, and (4) topical amphotericin 0.15% plus CXL. MAIN OUTCOME MEASURES: The primary outcome of the trial was microbiological cure at 24 hours on repeat culture. Secondary outcomes included best spectacle-corrected visual acuity (BSCVA) at 3 weeks and 3 months, percentage of study participants with epithelial healing at 3 days, 3 weeks, and 3 months, infiltrate or scar size at 3 weeks and 3 months, 3-day smear and culture, and adverse events. RESULTS: Those randomized to CXL regardless of medication (topical natamycin or amphotericin) had 1.32-fold increased odds of 24-hour culture positivity, although this was not statistically significant (95% confidence interval [CI], 0.57-3.06; P = 0.51). We were also unable to find a difference in 24-hour culture positivity between those randomized to amphotericin and those randomized to natamycin when evaluating as a group regardless of whether or not they received CXL (coefficient 1.10; 95% CI, 0.47-2.54; P = 0.84). The BSCVA was approximately 0.22 logarithm of the minimum angle of resolution (logMAR) (2.2 Snellen lines) worse on average at 3 weeks among those receiving CXL regardless of medication (95% CI, -0.04 to 0.40; P = 0.04) and 0.32 logMAR (3.2 Snellen lines) worse visual acuity at 3 months after controlling for baseline visual acuity (95% CI, 0.03-0.54; P = 0.02). There was no difference in infiltrate or scar size, percentage of epithelialized or adverse events when comparing CXL with no CXL or the 2 topical medications. CONCLUSIONS: There appears to be no benefit of adjuvant CXL in the primary treatment of moderate filamentous fungal ulcers, and it may result in decreased visual acuity.
引用
- Prajna NV, Radhakrishnan N, Lalitha P, et al. Cross-Linking-Assisted Infection Reduction: A Randomized Clinical Trial Evaluating the Effect of Adjuvant Cross-Linking on Outcomes in Fungal Keratitis. Ophthalmology. 2019. PMID: 31619359. doi:10.1016/j.ophtha.2019.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。